Stolt-Nielsen Limited Reports Unaudited Results For the Fourth Quarter and Full Year of 2015
Jan 28, 2016 07:23 am UTC| Business
LONDON, Jan. 28, 2016 -- Stolt-Nielsen Limited (Oslo Brs: SNI) today reported unaudited results for the fourth quarter ended November 30, 2015. Net profit attributable to shareholders in the fourth quarter was $21.4...
ING exchanges final tranche of NN Group anchor investment notes
Jan 28, 2016 07:09 am UTC| Business
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. AMSTERDAM, Netherlands, Jan. 28, 2016 -- ING announced today it will exchange...
COTA Enters Innovative Collaboration to Enhance Outcomes and Drive Value-Based Cancer Care
Jan 28, 2016 06:00 am UTC| Business
NEW YORK, Jan. 28, 2016 -- COTA Inc. (Cancer Outcomes Tracking and Analysis) and Novartis Pharmaceuticals Corporation have entered into an innovative collaboration with a goal to improve patient outcomes, enhance the...
Symbiont taps Gemalto to offer high-assurance security for blockchain-based services
Jan 28, 2016 06:00 am UTC| Business
AMSTERDAM, The Netherlands, Jan. 28, 2016 -- Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, and Symbiont, a pioneer in the use of blockchain and distributed ledger technology in capital...
Cosmetic Implants Market Size Worth USD 9.29 Billion By 2020
Jan 28, 2016 05:46 am UTC| Business Research & Analysis
San Francisco, Jan. 28, 2016 -- Global Cosmetic Implants Market is expected to reach USD 9.29 billion by 2020. Increasing demand for aesthetic procedures coupled with rising healthcare expenditure levels is expected to...
HMN Financial, Inc. Announces Fourth Quarter Results and Annual Meeting
Jan 28, 2016 04:30 am UTC| Business
Fourth Quarter Highlights Net income of $1.1 million compared to net income of $1.7 million for fourth quarter of 2014Diluted earnings per common share of $0.23 compared to diluted earnings per common share of $0.30 in...
Jan 28, 2016 02:27 am UTC| Business
SAN FRANCISCO, Jan. 27, 2016 -- FibroGen, Inc. (FibroGen) today announced early results from a Phase 2, randomized, open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine...